- Home
- NWBI vs NRIX Comparison
NWBI vs NRIX Comparison
Compare NWBI & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NWBI | NRIX |
|---|---|---|
| Founded | 1896 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NWBI | NRIX |
|---|---|---|
| Price | $13.01 | $19.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | $14.00 | ★ $29.08 |
| AVG Volume (30 Days) | 753.7K | ★ 1.2M |
| Earning Date | 01-26-2026 | 02-12-2026 |
| Dividend Yield | ★ 6.19% | N/A |
| EPS Growth | ★ 13.78 | N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $564,562,000.00 | $83,687,000.00 |
| Revenue This Year | $7.94 | $59.40 |
| Revenue Next Year | $8.90 | N/A |
| P/E Ratio | $14.96 | ★ N/A |
| Revenue Growth | 15.71 | ★ 48.32 |
| 52 Week Low | $10.75 | $8.18 |
| 52 Week High | $13.62 | $22.50 |
Technical Indicators
Market Signals| Indicator | NWBI | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 66.94 | 59.67 |
| Support Level | $12.13 | $18.12 |
| Resistance Level | $12.46 | $19.50 |
| Average True Range (ATR) | 0.29 | 1.05 |
| MACD | 0.08 | -0.04 |
| Stochastic Oscillator | 95.94 | 87.52 |
Price Performance
Historical ComparisonAbout NWBI Northwest Bancshares Inc.
Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution offering personal and commercial banking business solutions, investment management, trust services, and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and business banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Business banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.
About NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.